October 23, 2013
Local (JPN)

PDF (81KB)

For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Joji Nakayama, President and CEO
(Code no.: 4568, First Section, Tokyo Stock Exchange)
Please address inquiries to Noriaki Ishida, Corporate Officer,
Vice President, Corporate Communications Department
Telephone: +81-3-6225-1126
http://www.daiichisankyo.com

Daiichi Sankyo Selects Research Partners for TaNeDS Collaborative Drug Discovery Project

Tokyo, Japan (October 23, 2013) — Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has selected research partners for its TaNeDS (Take a New challenge for Drug diScovery) collaborative drug discovery project. The researchers were selected from universities and public research centers in Japan. Daiichi Sankyo will soon begin signing agreements with the selected parties to initiate collaborative research.

 

1. Total entries: 222

 

2. Selected parties: 23

 

3. Selections by entry type

 

 

Entries

Those that passed second selection

Final selections

A. Daiichi Sankyo's Desired Research Themes

215

33

20

B. RD Novare's Desired Research Themes*

7

3

3

Total

222

36

23

 

 

4. Selections by research theme

 

 

Entries

Those that passed second selection

Final selection

A. Daiichi Sankyo's Desired Research Themes

i. Oncology

 

71

 

9

 

5

ii. Cardiovascular metabolics

75

2

2

iii. Leading edge pharmaceuticals

57

4

3

iv. Enhancement of current research projects

44

5

3

v. Antibodies

37

7

2

vi. Nucleic acid therapeutics, peptide pharmaceuticals, DDS

40

3

2

vii. Biomarkers

41

0

0

viii. Drug Safety, ADME(Drug Absorption, Distribution, Metabolism, Excretion)

44

4

3

ix. Pharmaceutical technology platforms

0

0

0

B. RD Novare's Desired Research Themes

Drug discovery and development technology platform research

 

7

 

3

 

3

Total

(Entries with multiple themes are counted once for each theme)

419

36

23

 

 

* Daiichi Sankyo RD Novare Co., Ltd. (hereafter, RD Novare), Daiichi Sankyo’s wholly owned subsidiary, joined TaNeDS to promote the development of novel technology platforms for drug discovery, in 2013.

 

For reference: 2012 TaNeDS project overview (from March 6, 2013 press release)

 

1. Project overview

1) How to apply

 

Project type

Objective

Applicable person/group

Duration

Scope of funding (total)

A. Daiichi Sankyo's Desired Research Themes

Feasibility research

Discovery and development of initial drug discovery themes and new technologies

Researchers in Japan

Completion of contract to March 31, 2015

Up to 10 million yen

Collaborative research

Discovery and development of initial drug discovery themes and new technologies in collaboration with Daiichi Sankyo

Researchers and research teams in Japan

Completion of contract for one or two years*

Up to 20 million yen (up to 10 million yen per year)

B. RD Novare's Desired Research Themes

Feasibility research

Drug discovery and development technology platforms

Researchers in Japan

Completion of contract to March 31, 2015

Up to 5 million yen

 

*Project duration subject to change based on research

Target project numbers: 18 for A, and 2 for B

 

A. Desired research themes by Daiichi Sankyo: 1) Exploratory research themes and research themes that will lead to initial drug discovery in the idea stage; 2) research themes that will lead to practical application of intellectual properties and proprietary know-how; and 3) technologies being researched academically that are applicable to solving challenges faced in terms of pharmaceutical manufacturing process development and quality assurance will be accepted. Daiichi Sankyo will determine if feasibility studies with Daiichi Sankyo researchers (preliminary collaborative research) or collaborative research should be conducted based on proposed themes. Accepted themes will be selected for continuation based on results after the research period comes to a close.

 

B. Desired research themes by RD Novare: Research themes that will lead to the development of the novel technology platforms related to drug discovery will be accepted. Scientists at RD Novare work together on technological seeds being researched academically by applicants to establish leading edge technology platforms and biological evaluation methods.

 

2) Desired research themes

 

- Desired research themes by Daiichi Sankyo

i. Oncology

ii Cardiovascular metabolics (metabolic disease, heart disease and vascular disease)

iii Leading edge pharmaceuticals

iv Enhancement of current research projects

v Antibodies

vi Nucleic acid therapeutics, peptide pharmaceuticals, DDS

vii Biomarkers

viii Drug Safety, ADME (Drug Absorption, Distribution, Metabolism, Excretion)

ix Pharmaceutical technology platforms

 

- Desired research themes by RD Novare

i. Drug discovery and development technology platform research

 

* For more information about the TaNeDS program visit the Daiichi Sankyo corporate website: https://www.daiichisankyo.co.jp/corporate/rd/taneds/

 

3) Who is eligible

Researchers from universities and public research centers who can conduct research in Japan

 

4) Schedule

Application period:               May 20 to June 14, 2013

First selection period:         June 17 to July 31, 2013

Second selection period:    August 1 to September 30, 2013

Contract negotiation:           From October 1, 2013

Start of research:                 Upon completion of contract

 

*For more information about the TaNeDS program visit the Daiichi Sankyo corporate website: https://www.daiichisankyo.co.jp/rd/taneds/index.html (Japanese only)

 

 

Back to index